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Accurate diagnosis of tuberculosis (TB) infection is critical for the treatment, prevention, and control of TB.
Conventional diagnostic tests based on purified protein derivative (PPD) do not achieve the required diag-
nostic sensitivity. Therefore, in this study, we have evaluated the immunogenic properties of Rv1168c, a
member of the PPE family, in comparison with PPD, which is routinely used in the tuberculin test, and Hsp60
and ESAT-6, well-known immunodominant antigens of Mycobacterium tuberculosis. In a conventional enzyme
immunoassay, the recombinant Rv1168c protein displayed stronger immunoreactivity against the sera ob-
tained from patients with clinically active TB than did PPD, Hsp60, or ESAT-6 and could distinguish TB
patients from Mycobacterium bovis BCG-vaccinated controls. Interestingly, Rv1168c antigen permits diagnosis
of smear-negative pulmonary TB as well as extrapulmonary TB cases, which are often difficult to diagnose by
conventional tests. The immunodominant nature of Rv1168c makes it a promising candidate to use in
serodiagnosis of TB. In addition, our studies also show that Rv1168c is a potent T-cell antigen which elicits a
strong gamma interferon response in sensitized peripheral blood mononuclear cells obtained from TB patients.
Tuberculosis (TB) remains a significant global public health
concern and is a major cause of death in adults by a single
bacterial agent (39). The increasing global health burden of
tuberculosis is further aggravated by the alarming increase in
human immunodeficiency virus infection as well as the emer-
gence of drug-resistant strains of Mycobacterium tuberculosis
(16, 18). One of the best prognoses for tuberculosis comes with
early diagnosis of the infection and immediate implementation
of appropriate treatment regimens. The diagnosis of the ma-
jority of TB cases in developing countries like India relies on
acid-fast staining of sputum or positive cultures of M. tubercu-
losis in conjunction with assessment of clinical symptoms and
radiographic evidence (6, 29, 38). However, these evaluations
are usually expensive, tedious, and time-consuming. The most
common method employed for detection of M. tuberculosis
infection is the purified protein derivative (PPD) or tuberculin
skin test, but PPD is a crude and poorly defined mixture of
mycobacterial antigens, many of which are shared with pro-
teins from the vaccine strain Mycobacterium bovis bacillus
Calmette-Gue´rin (BCG) and from nontuberculous environ-
mental mycobacteria (20, 22). Therefore, the clinical relevance
of the tuberculin test with PPD is not highly reliable (17, 30).
Although several new and rapid tests for the diagnosis of TB
have been developed in recent years (7, 25, 33), they must be
performed in laboratories and involve costly equipment and
reagents. Further, most of the antigens in these tests have poor
sensitivity and specificity to diagnose TB cases with smear-
negative sputum samples and are not yet considered standard
practice (4, 8). A serological test to detect antibodies to M.
tuberculosis has the immense potential to make a diagnostic
test for TB optimal and low-cost in developing countries, es-
pecially under field conditions (10). In recent years, numerous
M. tuberculosis antigens that are capable of generating specific
antibody titers in TB patients have been identified, but no
single antigen appears to be ideal for serodiagnostic assays (13,
21, 26). Therefore, identification of an appropriate M. tuber-
culosis antigen suitable for serodiagnosis that can offer high
specificity, ease of detection, and sensitivity that can distin-
guish active tuberculosis patients from BCG-vaccinated con-
trols is highly desirable for developing suitable control
measures and early treatment of the disease.
A significant portion (10%) of the Mycobacterium tubercu-
losis genome encodes two unique protein families, the PE and
PPE families, with no known apparent functions (11). The
PE/PPE genes are expressed upon various environmental cues
during infection, and many of the PPE proteins have been
found to be strongly immunogenic (10, 12, 15, 32). Recently,
studies have shown that mycobacterial PPE antigen Rv1168c
(PPE 17) is associated with ESAT-6 gene cluster region 5
(ESX-5) (19), which is predicted to encode a novel secretory
apparatus (1, 19). It has also been shown that this cluster is
conserved among the various pathogenic mycobacteria, but not
in the saprophytic species Mycobacterium smegmatis (1). Fur-
ther, a BLAST analysis suggested that no genes that are
strongly homologous to Rv1168c are present in the non-TB
mycobacterial species that have been sequenced. The absence
of homologues in other mycobacterial species, such as Myco-
bacterium avium, makes this protein a potential candidate for
serological diagnosis of TB, which is further corroborated by
its high antigen index, as calculated with the Kyte-Doolittle
algorithm. Interestingly, the recent microarray and proteome
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studies have shown that Rv1168c is up-regulated under mi-
croaerophilic and anaerobic conditions (2, 31), nutrient star-
vation (5), and in the presence of palmitic acid (35), which
simulates the features of the phagosomal environment. This
information provides a strong justification for the expression of
this gene during M. tuberculosis infection. Therefore, in the
present study we have examined whether Rv1168c provides a
highly sensitive means of diagnosing patients with active TB.
MATERIALS AND METHODS
Cloning, expression, and purification of recombinant Rv1168c and Hsp60
protein. The open reading frame corresponding to Rv1168c was PCR amplified
from the genomic DNA of H37Rv. XhoI and HindIII restriction sites were
incorporated in the 5 ends of the forward and reverse primers, respectively. The
primers were as follows: forward, GACTCGAGATGGATTTCACAATTTTT;
reverse, GCAAGCTTCTAGCCGGCGGCGGGTGACCGCAGT. The param-
eters for thermal cycle amplification were as follows: 94°C for 12 min; 10 cycles
of 94°C for 30 s, 42°C for 30 s, and 72°C for 1 min; 20 cycles of 94°C for 30 s, 37°C
for 30 s, and 72°C for 1 min; and a final step at 72°C for 30 min. The size of the
amplicon generated was approximately 1,041 bp. The PCR product was first
directly cloned in intermediate pGEM-T Easy vectors (Promega, Madison, WI),
followed by subcloning in the bacterial expression vector pRSET-A (Invitrogen,
Carlsbad, CA) in frame with an N-terminal six-histidine tag using XhoI and
HindIII. The clones were validated by sequencing with the T7 promoter primer
on an Applied Biosystems Prism 377 DNA sequencer. The pRSET-A clone was
then transformed in an Escherichia coli BL21(DE3)pLys expression system. The
transformed cells were grown in Terrific broth containing ampicillin (100 g/ml)
and chloramphenicol (35 g/ml) at 37°C on a shaker to an optical density at 600
nm (OD600) of 0.4 to 0.6, induced with 1 mM isopropyl--D-thiogalactopyrano-
side (Sigma-Aldrich), and further grown at 37°C for 3 to 4 h. The cells were lysed,
and induction of Rv1168c was checked (Fig. 1A). Polyhistidine-tagged recombi-
nant protein was purified using Talon resin (BD Biosciences Clontech) according
to the manufacturer’s recommendations for purification of protein under native
conditions. The purity of the protein was confirmed by loading onto a 10%
sodium dodecyl sulfate gel. A single protein band with a molecular mass of 42
kDa corresponding to Rv1168c protein was observed. The yield of protein was 6
mg/liter culture and appeared to be 98% pure (Fig. 1A). The mycobacterial heat
shock protein 60 (Hsp60) was purified (Fig. 1B) as described previously (34). The
purified recombinant early secretory antigenic target 6 (ESAT-6) protein of M.
tuberculosis was a kind gift from Pawan Sharma, ICGEB, New Delhi, India.
Protein concentrations were estimated using the bicinchoninic acid method
(Micro BCA protein assay kit; Pierce, Rockford, IL). To remove endotoxin
contamination, purified Rv1168c, Hsp60, or ESAT-6 protein was incubated with
10% (vol/vol) polymyxin B-agarose (Sigma-Aldrich; binding capacity, 200 to 500
g of lipopolysaccharide from Escherichia coli serotype O128:B12/ml) for 1 h at
4°C, and the protein preparation was used to assess the B-cell or T-cell response.
Study population. The study population (n  109) was comprised of pulmo-
nary (n  77) and extrapulmonary (n  32) tuberculosis patients diagnosed at
the DOTS (directly observed treatment, short course) Clinic of Mahavir Hospital
and Research Centre, Hyderabad, India. The diagnosis of the patients with
pulmonary TB was based on the results of a sputum smear examined for the
presence of acid-fast bacilli, radiographic examination, and clinical symptoms as
per the Revised National TB Control Programme guidelines, Central TB Divi-
sion, Directorate General of Health Services, Ministry of Health and Family
Welfare, Government of India (http://www.tbcindia.org). The extrapulmonary
cases were confirmed by tissue biopsy, clinical symptoms, and radiographic evi-
dence (http://www.tbcindia.org). All the subjects were found to be negative for
human immunodeficiency virus. Sera were collected from the patients just before
initiation of chemotherapeutic regimen. All the patients responded to the DOTS
regimen, and at the time of preparation of the manuscript, the patients were
considered cured based on relief from clinical symptoms, absence of the acid-fast
bacillus in the sputum, and radiographic examination. Control sera (n 20) were
collected from volunteers from regions endemic for TB. All the control subjects
were BCG vaccinated and had no clinical symptoms of TB at the time of sample
collection. The bioethics committee of Mahavir Hospital and Research Centre
and CDFD approved the present study, and written informed consent was ob-
tained from all the subjects.
EIA. For the enzyme immunoassay (EIA), 96-well microtiter plates (Costar,
Corning, NY) were coated with 0.5 g/well recombinant Rv1168c, ESAT-6, or
Hsp60 protein or PPD (diluted in 0.1 M carbonate buffer, pH 9.5, with 50 l
added to each well) (10). Plates were incubated overnight at 4°C, washed three
times with phosphate-buffered saline (PBS), and blocked with 100 l of blocking
buffer (PBS containing 2% bovine serum albumin) for 2 h at 37°C. After washing
the plates three times with PBS containing 0.05% Tween 20 (PBS-T; Sigma-
Aldrich), sera (diluted 200-fold in blocking buffer) from various study groups
were added (50 l) to antigen-coated wells in duplicate and incubated for 1 h at
37°C. The plates were washed three times with PBS-T and incubated with 50 l
of anti-human immunoglobulin G (IgG)–horseradish peroxidase (HRP; Sigma-
Aldrich) conjugate (1:8,000 dilution in blocking buffer) for 1 h at 37°C. The
plates were washed two times with PBS-T, and a final wash was carried out with
PBS. The HRP activity was detected using a chromogenic substance, o-phenyl-
enediamine tetrahydrochloride (Sigma-Aldrich) in citrate-phosphate buffer (pH
5.4) and H2O2 (Merck, Germany) as substrate (1 l/ml). Reactions were termi-
nated using 1 N H2SO4, and the absorbance values were measured at 492 nm
with an EIA reader (Bio-Tek Instruments Inc., VT).
Cytokine assay. The peripheral blood mononuclear cells (PBMCs) from TB
patients (n  35) and BCG-vaccinated controls (n  10) were isolated using
density gradient centrifugation in Ficoll-Hypaque solution (Sigma-Aldrich) as
described elsewhere (9) and prepared at 2.5  106 cells/ml in RPMI 1640
medium (Invitrogen, Grand Island, NY) containing 10% fetal bovine serum
(Invitrogen) and antibiotics (RPMI-10). Cell suspensions (200 l/well) were
dispensed into 96-well, flat-bottom microtiter plates (Nunc, Roskilde, Denmark)
and maintained at 37°C in a 5% CO2 incubator. PBMCs from various groups
were treated with a fixed concentration of Rv1168c (3 g/ml) or PPD, and after
4 days culture supernatants were harvested for estimating gamma interferon
(IFN-) and interleukin-5 (IL-5) cytokine levels secreted in the culture super-
natants using the EIA. The cytokine was quantified by a two-site sandwich EIA
(BD Biosciences Pharmingen, San Diego, CA) following the manufacturer’s
protocol as described by us previously (24). Briefly, 96-well polyvinyl chloride
FIG. 1. Expression and purification of M. tuberculosis proteins
Rv1168c (A) and Hsp60 (B). The recombinant protein was expressed
in strain BL21 of Escherichia coli and was purified to homogeneity
using the Ni-nitrilotriacetic acid protein purification kit. Results shown
are for Coomassie blue-stained sodium dodecyl sulfate gels showing
uninduced (UN) and induced (IN) cell lysates, a protein molecular size
marker (M), and different lanes showing different elution fractions
containing purified protein (lanes 1 to 7 in panel A and lanes 1 to 5 in
panel B) obtained during purification of the respective proteins. The
arrow on the right indicates the position of the Rv1168c protein (42
kDa) or Hsp60 protein (60 kDa).
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microtiter plates were coated with purified anticytokine antibody at a 2-g/ml
concentration. The plates were blocked with 2% bovine serum albumin in PBS
and incubated with various culture supernatants followed by incubation with
biotin-conjugated anticytokine antibody and streptavidin-HRP. The HRP activ-
ity was detected using o-phenylenediamine tetrahydrochloride, and absorbance
was read at 492 nm. A standard curve for the cytokine was obtained using the
IFN- or IL-5 recombinant standard protein provided by the manufacturer.
Statistical analysis. For evaluation of antibody responses, cutoff values were
calculated for each antigen as the means of OD492 values obtained with the sera
from 20 BCG-vaccinated controls plus 6 standard deviations (SD) (27, 28). Data
were analyzed with Student’s t test or analysis of variance, as indicated below. A
P level of 	0.05 was considered significant.
RESULTS
Rv1168c shows a strong immunoreactivity toward TB pa-
tient sera compared to that of BCG-vaccinated controls. Based
on its predominant expression under the conditions that mimic
the in vivo phagosomal environment (2, 5, 31, 35) and its high
antigenicity index, we expected Rv1168c to induce a strong
B-cell response in people with active TB infection. Therefore,
we examined specific antibody reactivity in responses to
Rv1168c protein in sera from TB patients and compared this
with the BCG-vaccinated controls. The sensitivity and speci-
ficity of Rv1168c immunoreactivity were compared with the
responses elicited by ESAT-6, Hsp60, and PPD. The antibody
titers (Fig. 2A) against Rv1168c were found to be significantly
higher (absorbance at 492 nm [OD492] 
 SD, 1.05 
 0.381
[mean 
 SD]) in TB patients compared to that of the BCG-
vaccinated control sera (0.373 
 0.066; P 	 0.0001).
We also compared the serological reactivity of Rv1168c to
that elicited by two other mycobacterial immunodominant an-
tigens, ESAT-6 (which is a better-studied antigen and has
progressed to use commercially [7, 12]) and Hsp60 (3), and the
conventionally used PPD. The levels of anti-PPD antibodies
were found to be low in TB patients (OD492, 0.415 
 0.184),
indicating that PPD was not very sensitive in diagnosis of active
TB, which was in agreement with other reports (10, 28). Al-
though ESAT-6 (OD492, 0.612 
 0.264) was a better discrim-
inatory antigen than PPD, the sera of the patients reacted
much more strongly against Rv1168c than ESAT-6 (Fig. 2A).
Similarly, Hsp60, although it showed a better response (OD492,
0.571 
 0.230) than PPD, had a lower reactivity than Rv1168c
in the majority of the TB patients (Fig. 2B, panels i to iii). The
sera of the patients reacted very strongly against Rv1168c com-
pared to ESAT-6, Hsp60, and PPD (P 	 0.0001 for all cases).
Therefore, the Rv1168c protein appeared to be more efficient
in discriminating active tuberculosis patients from the BCG-
vaccinated controls, compared to Hsp60 and PPD. When the
proportion of highly reactive sera (antibody levels greater than
or equal to the mean OD492 of BCG-vaccinated control sera
plus 6 SD) among responders to each antigen was calculated,
it was observed that Rv1168c elicited high-level antibody re-
sponses in the majority (75.2%) of responders, compared to
PPD (14%), Hsp60 (24%), and ESAT-6 (33.1%) (Fig. 2C).
Thus, it appears that Rv1168c is more immunodominant and
serologically more sensitive than PPD, Hsp60, and ESAT-6.
Rv1168c can be used to diagnose extrapulmonary TB in
patients serologically. Since the recombinant Rv1168c protein
was found to be seroreactive against most of the TB patients,
we compared the antibody titers specific to Rv1168c in well-
defined clinical categories, such as pulmonary and extrapulmo-
nary cases. Due to limitations of the current array of diagnostic
methods, diagnosis of extrapulmonary cases (since most are
sputum negative) is more difficult than for pulmonary TB.
Therefore, a diagnostic method with potential to identify pa-
tients with extrapulmonary TB would be highly valuable. We
found that Rv1168c elicited stronger antibody responses in
extrapulmonary TB cases, as well as in the pulmonary TB
cases, than did the BCG-vaccinated controls (Fig. 3) (P 	
0.0001 in both cases). The mean absorbance values for
Rv1168c in control, pulmonary, and extrapulmonary groups
were 0.373, 1.01, and 1.15, respectively (Fig. 3). As shown in
Table 1, when the immunogenicities of Rv1168c versus
ESAT-6, Hsp60, and PPD were compared, the mean reactivity
of Rv1168c was significantly higher than those of ESAT-6 (P	
0.0001), Hsp60 (P 	 0.0001), and PPD (P 	 0.0001) in both
pulmonary and extrapulmonary TB patient sera. When ex-
pressed as percentages of high-level responders showing anti-
body levels greater than or equal to cutoff values (mean OD492
of BCG-vaccinated control sera plus 6 SD), the majority of the
FIG. 2. The PPE protein Rv1168c is more sensitive for discriminating TB patients from the BCG-vaccinated controls. The scatter plot shows
the serum cross-reactivities by EIA to the mycobacterial recombinant Rv1168c, mycobacterial recombinant ESAT-6, Hsp60, and PPD with serum
from either active tuberculosis patients or BCG-vaccinated controls. The horizontal line indicates the mean of the absorbance values (A). The EIA
antibody responses of individual patients whose results are shown in panel A were compared between Rv1168c and Hsp60 (B, panels i to iii).
Responders to Rv1168c were compared with that of ESAT-6, Hsp60, and PPD by calculating the percentage of TB patients showing absorbance
value greater than or equal to the cutoff value, calculated as the mean OD492 of control sera plus 6 SD (C). Mean OD492 (SD) values used for cutoff
determinations were as follows: Rv1168c, 0.376 (0.066); ESAT-6, 0.343 (0.07), Hsp60, 0.359 (0.08); PPD, 0.295 (0.071). Statistical significance was
determined with Student’s t test.
FIG. 3. Rv1168c is a better antigen to diagnose pulmonary as well
as extrapulmonary TB cases. The EIA absorbance values at 492 nm
shown in Fig. 2A were replotted to compare Rv1168c-specific immune
responses of pulmonary and extrapulmonary TB patients with that of
BCG-vaccinated controls. Statistical significance was determined with
an analysis of variance.
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pulmonary (73%) and extrapulmonary (81.3%) TB cases
showed antibody levels greater than the cutoff value against
Rv1168c antigen, whereas only 37.6 and 21.9% responders had
higher levels against ESAT-6, 27.2 and 16% against Hsp60,
and 14.3 and 12.5% against PPD, respectively (Table 1). As
with extrapulmonary TB, diagnosis of smear-negative pulmo-
nary TB cases is also tedious and difficult. We, therefore,
checked whether anti-Rv1168c antibody titers were higher in
the smear-negative pulmonary TB. Interestingly, we also found
that Rv1168c was more sensitive than ESAT-6, Hsp60, and
PPD in diagnosing the smear-negative pulmonary TB patients.
It was found that in smear-negative TB patients (n  24),
serum samples from 75% of the patients had antibodies to
Rv1168, whereas only 45.8% of patients had antibodies to
ESAT-6, 25% of patients had antibodies to Hsp60, and 21% of
patients had antibodies to PPD (Table 1). In the cohort of
smear-positive TB patients (n  53), 71.6% possessed
Rv1168c-specific antibodies, 34% had ESAT-6-specific anti-
bodies, 28.3% had Hsp60-specific antibodies, and 9.4% had
PPD-specific antibodies (Table 1). These results indicate that
Rv1168c can potentially be used in the diagnosis of all the
categories of TB cases, including smear-negative pulmonary,
smear-positive pulmonary, and extrapulmonary TB cases, with
higher sensitivity than ESAT-6, Hsp60, or PPD.
The PPE antigen Rv1168c triggers a strong T-cell response
in TB patients as opposed to BCG-vaccinated controls. In vitro
tests that measure IFN- production by whole blood cells have
recently being used to diagnose active TB cases (14, 23). We
observed that Rv1168c triggered stronger antibody responses
of the IgG type in patients with active TB (Fig. 2 and 3). It is
known that IgG isotype switching requires a direct interaction
from T cells (14). Therefore, there is a possibility that Rv1168c
can also induce stronger T-cell responses in TB patients.
Therefore, we measured T-cell responses of TB patients (with
pulmonary tuberculosis and extrapulmonary tuberculosis), as
indicated by the amounts of cytokines secreted in vitro, and
BCG-vaccinated controls. We found that IFN- levels in both
pulmonary (mean, 287 pg/ml) and extrapulmonary (mean, 325
pg/ml) TB patients were elevated more than threefold com-
pared with the levels (mean, 92 pg/ml) in BCG-vaccinated
controls (Table 2) (P 	 0.0001 in both cases). Similarly, IL-5
levels were also significantly elevated (Table 2) (P	 0.0001) in
both pulmonary (mean, 147 pg/ml) and extrapulmonary
(mean, 191 pg/ml) TB patients compared with the BCG-vac-
cinated controls (mean, 80 pg/ml). Also, it was observed that
compared to PPD, Rv1168c was a potent T-cell antigen for
diagnosing active TB cases (Table 2). These data indicate that
T cells from TB patients respond dominantly against the my-
cobacterial Rv1168c protein and can distinguish TB patients
from BCG-vaccinated controls.
DISCUSSION
There is a need to develop newer and more efficient diag-
nostic tests that can identify most of the TB cases with better
specificity and sensitivity. Although a number of potential M.
tuberculosis antigens have been studied extensively in the past,
most of them are not suitable to distinguish between BCG-
vaccinated controls and active TB populations with sufficient
specificity due to their heterogeneous responses, especially
from patients with various clinical grades of TB.
Predominant expression under conditions that mimic the in
vivo environment (2, 31, 35), and expression restricted to the
Mycobacterium complex, makes Rv1168c an attractive candi-
date for serodiagnosis to discriminate TB patients from BCG-
vaccinated individuals. Therefore, in the present study we eval-
uated the immunological potential of Rv1168c antigen as a
diagnostic marker in a cohort of clinically defined active TB
patients and BCG-vaccinated controls. Our data demonstrate
that compared to conventional diagnostic tests using PPD,
TABLE 1. Rv1168c can potentially be used to diagnose smear-positive and smear-negative pulmonary as well as extrapulmonary TB casesa
Antigen
Total extrapulmonary
TB cases (n  32)
Total pulmonary
TB cases (n  77)
Smear-positive pulmonary
TB cases (n  53)
Smear-negative pulmonary
TB cases (n  24)
Mean 
 SD % Responders Mean 
 SD % Responders Mean 
 SD % Responders Mean 
 SD % Responders
Rv1168c 1.15 
 0.38 81.3 1.01 
 0.38 73.0 1.01 
 0.36 71.6 1.03 
 0.42 75.0
ESAT-6 0.62 
 0.22 21.9 0.61 
 0.28 37.6 0.60 
 0.26 34.0 0.64 
 0.32 45.8
Hsp60 0.52 
 0.22 16.0 0.59 
 0.23 27.2 0.61 
 0.22 28.3 0.56 
 0.24 25.0
PPD 0.41 
 0.17 12.5 0.42 
 0.19 14.3 0.40 
 0.16 9.4 0.46 
 0.23 21.0
a The data from Fig. 2A were replotted to compare the antibody responses of the pulmonary and extrapulmonary TB patients against Rv1168c versus ESAT-6, Hsp60,
and PPD. The percentage of responders showing absorbance values greater than or equal to the cutoff value (mean OD492 plus 6 SD, based on results with
BCG-vaccinated control sera) was compared for pulmonary and extrapulmonary TB groups. The pulmonary TB cases were further categorized as smear positive and
smear negative, and responders to Rv1168c were compared with those for ESAT-6, Hsp60, and PPD by calculating the percentage of individuals showing absorbance
values greater than or equal to the mean OD492 plus 6 SD (obtained with BCG-vaccinated control sera).
TABLE 2. Rv1168c mounts stronger T-cell responses in TB patients than in BCG-vaccinated controlsa
Antigen
Controls Pulmonary TB patients Extrapulmonary TB patients
IFN- (pg/ml) IL-5 (pg/ml) IFN- (pg/ml) IL-5 (pg/ml) IFN- (pg/ml) IL-5 (pg/ml)
Rv1168c 92 
 24 80 
 22 287 
 70 147 
 69 325 
 125 191 
 61
PPD 91 
 17 78 
 19 177 
 52 81 
 31 141 
 51 106 
 50
a PBMCs collected from TB patients and BCG-vaccinated controls were stimulated in triplicate with 3 g/ml of Rv1168c or 10 g/ml PPD. After 4 days, levels of
IFN- and IL-5 cytokines secreted in the culture supernatants were estimated by EIA.
978 KHAN ET AL. CLIN. VACCINE IMMUNOL.
 o
n
 January 24, 2017 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
recombinant Rv1168c is highly sensitive for distinguishing pa-
tients with active tuberculosis from BCG-vaccinated controls.
In addition, recombinant Rv1168c was found to be more sen-
sitive than ESAT-6 and Hsp60 (well-known immunodominant
antigens of M. tuberculosis) for recognizing TB patients from
BCG-vaccinated controls. Interestingly, although a homologue
of Rv1168c is present in M. bovis, we found a negligible im-
munological response to this protein in BCG-vaccinated indi-
viduals, indicating that Rv1168c is probably highly expressed
during the active pathogenesis of M. tuberculosis. Our results
suggest that Rv1168c antigen should be considered an attrac-
tive candidate for development of new diagnostic tests that can
identify people suffering from the active form of disease in
regions endemic for TB.
Despite the initial clinical suspicion of TB, when a patient’s
sputum smear results are negative for acid-fast bacilli, the
diagnosis of TB may not be made. Therefore, it is important to
continue research for a rapid and reliable immunological test
to diagnose the smear-negative TB cases (23, 37). The recent
approaches using ESAT-6 and CFP-10 as diagnostic antigens
are useful mostly as a means to diagnose either latent infection
or sputum-positive pulmonary infection, and not much infor-
mation is available regarding use of these antigens to diagnose
smear-negative cases with higher sensitivity (14, 23, 37). We
found that Rv1168c could diagnose extrapulmonary and
smear-negative pulmonary TB cases with higher sensitivity
than ESAT-6 or Hsp60 immunodominant antigen. A very high
percentage of the serum samples obtained from the extrapul-
monary and the smear-negative pulmonary TB patients had
strong antibody reactivities against Rv1168c protein compared
to ESAT-6, Hsp60, and PPD, indicating that Rv1168c can be
used to potentially diagnose these categories of TB patients
with higher sensitivity and can discriminate smear-negative
pulmonary as well as extrapulmonary TB patients from the
BCG-vaccinated controls. Thus, our findings are particularly
significant in the context of smear-negative pulmonary and
extrapulmonary TB cases, which often go undiagnosed with
conventional diagnostic methods (4, 8).
Also, it is well-established that the generation of substantive
antibody responses to a protein antigen is dependent on the
presence of T-cell epitopes recognized by helper T cells (14).
We found that Rv1168c was also a potent T-cell antigen, elic-
iting higher levels of IFN- in PBMCs obtained from TB
patients in contrast to those obtained from BCG-immunized
controls. Thus, Rv1168c is also a dominant T-cell antigen rec-
ognized by most of the TB patients, and this reflects that
Rv1168c possibly plays an important role in certain stages of
mycobacterial infection and intracellular survival.
Recently, a few PPE proteins have been studied for their
suitability for use in serological diagnosis of TB patients. In-
terestingly, we found that Rv1168c is more potent in detecting
both pulmonary and extrapulmonary TB cases than some of
the earlier-studied PPE proteins, viz., Rv3425 (40), Rv2608 (9),
and Rv2430 (10), in enzyme immunoassays and shows compa-
rable immunogenicity to only Rv3872 (28). In our studies, we
have used a more stringent cutoff (OD plus 6 SD) to discrim-
inate patient sera from BCG-vaccinated control sera, and still
a significantly higher percentage of TB patients (both pulmo-
nary and extrapulmonary cases) could be diagnosed by Rv1168c
compared to the above-mentioned candidate PPE proteins, for
which the calculations were done using a less stringent cutoff
value (OD plus 3 SD). This suggests that the Rv1168c protein
is practically more sensitive for distinguishing patient sera from
the BCG-immunized control sera. Interestingly, Singh et al.
(36) have shown that the presence of anti-PPE55 antibodies
can serve to distinguish between latent TB and incipient, sub-
clinical TB. Though we have not evaluated the ability of
Rv1168c to differentiate such cases, none of the previous stud-
ies reported the ability of PPE proteins to be used in diagnosis
of smear-negative TB cases, which are difficult to diagnose with
the available diagnostic methods. However, we have observed
that Rv1168c can be used to diagnose almost 75% of the
smear-negative cases effectively. Nonetheless, our data also
suggest that Rv1168c is a potent T-cell antigen which elicits a
strong IFN- response in sensitized PBMCs obtained from TB
patients. It will be interesting to compare the IFN- responses
from other PPE antigens with that to Rv1168c.
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